CG
KRYS icon

Cynosure Group’s Krystal Biotech KRYS Stock Holding History

Cynosure Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$426K Sell
1,649
-757
-31% -$201K 0.05% 121
2025
Q4 		$593K Sell
2,406
-3,512
-59% -$739K 0.06% 114
2025
Q3 		$1.04M Hold
5,918
– – 0.11% 70
2025
Q2 		$813K Buy
5,918
+2,016
+52% +$296K 0.09% 115
2025
Q1 		$704K Buy
3,902
+272
+7% +$45.8K 0.1% 105
2024
Q4 		$569K Sell
3,630
-359
-9% -$63.7K 0.09% 123
2024
Q3 		$726K Sell
3,989
-335
-8% -$64.6K 0.11% 116
2024
Q2 		$794K Buy
4,324
+557
+15% +$93.5K 0.13% 99
2024
Q1 		$670K Buy
+3,767
New +$523K 0.12% 99

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cynosure Group's KRYS Position: Q1 2026 in Review

Cynosure Group reduced its Krystal Biotech (KRYS) stake by 31% in Q1 2026, selling an estimated $201K and leaving 1,649 shares worth $426K. The position accounts for 0.05% of the portfolio, ranked #121.

Cynosure Group first reported a position in KRYS in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.04M in Q3 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Cynosure Group held 1,649 shares of Krystal Biotech worth $426K as of Q1 2026.
  • Cynosure Group sold 757 Krystal Biotech shares in Q1 2026, an estimated $201K.
  • Krystal Biotech made up 0.05% of Cynosure Group's portfolio in Q1 2026, its #121 holding.
  • Cynosure Group first reported a position in Krystal Biotech in Q1 2024 and has held it in 9 quarters since.
  • Cynosure Group's Krystal Biotech position peaked at $1.04M in Q3 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.